{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T03:45:09Z","timestamp":1793850309193,"version":"4.6.1"},"reference-count":52,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T00:00:00Z","timestamp":1631491200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.ygyno.2021.08.024","type":"journal-article","created":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T13:32:05Z","timestamp":1633440725000},"page":"246-253","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":122,"title":["Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer"],"prefix":"10.1016","volume":"163","author":[{"given":"Payal D.","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie L.","family":"Wethington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheyenne","family":"Pagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawar","family":"Latif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janos","family":"Tanyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lainie P.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Haggerty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haley","family":"Zarrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Domchek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronny","family":"Drapkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ie-Ming","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Dean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Gaillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew A.","family":"Torigian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Ting","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Giuntoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Simpkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2021.08.024_bb0005","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0090-8258(02)00091-4","article-title":"A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study","volume":"88","author":"Rose","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.08.024_bb0010","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1200\/JCO.1998.16.2.405","article-title":"Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study","volume":"16","author":"Rose","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2021.08.024_bb0015","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1200\/JCO.2006.09.6735","article-title":"Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer","volume":"25","author":"Mutch","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2021.08.024_bb0020","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1200\/JCO.2007.13.6606","article-title":"Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer","volume":"26","author":"Ferrandina","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2021.08.024_bb0025","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ygyno.2005.10.036","article-title":"Phase II trial of weekly paclitaxel (80 mg\/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study","volume":"101","author":"Gynecologic Oncology","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.08.024_bb0030","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ygyno.2007.08.062","article-title":"Weekly topotecan for recurrent platinum resistant ovarian cancer","volume":"108","author":"Abushahin","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.08.024_bb0035","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3802\/jgo.2013.24.3.258","article-title":"The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer","volume":"24","author":"Barber","year":"2013","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.08.024_bb0040","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2021.08.024_bb0045","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2021.08.024_bb0050","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(11)70214-5","article-title":"Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study","volume":"12","author":"Gelmon","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ygyno.2021.08.024_bb0055","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian Cancer","volume":"381","author":"Gonzalez-Martin","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2021.08.024_bb0060","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation","volume":"33","author":"Kaufman","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2021.08.024_bb0065","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2021.08.024_bb0070","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2021.08.024_bb0075","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2021.08.024_bb0080","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance Olaparib in patients with newly diagnosed advanced ovarian Cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2021.08.024_bb0085","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S1470-2045(19)30029-4","article-title":"Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial","volume":"20","author":"Moore","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ygyno.2021.08.024_bb0090","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ygyno.2017.08.022","article-title":"Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: integrated analysis of data from study 10 and ARIEL2","volume":"147","author":"Oza","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.08.024_bb0095","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ygyno.2021.08.024_bb0100","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.ygyno.2021.08.024_bb0105","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.molonc.2011.07.001","article-title":"The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings","volume":"5","author":"Helleday","year":"2011","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ygyno.2021.08.024_bb0110","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by clinical PARP inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2021.08.024_bb0115","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus Bevacizumab as first-line maintenance in ovarian Cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2021.08.024_bb0120","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(10)60893-8","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial","volume":"376","author":"Audeh","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2021.08.024_bb0125","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research N","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2021.08.024_bb0130","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1200\/JCO.2009.26.9589","article-title":"Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval","volume":"28","author":"Fong","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2021.08.024_bb0135","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1038\/s41467-021-22582-6","article-title":"Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (parts 1 and 2)","volume":"12","author":"Swisher","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ygyno.2021.08.024_bb0140","doi-asserted-by":"crossref","first-page":"5507","DOI":"10.1200\/JCO.2019.37.15_suppl.5507","article-title":"Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-resistant ovarian cancer","volume":"37","author":"Vanderstichele","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2021.08.024_bb0145","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41568-018-0034-3","article-title":"Targeting ATR in cancer","volume":"18","author":"Lecona","year":"2018","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2021.08.024_bb0150","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-20-0868","article-title":"First-in-Human Trial of the Oral Ataxia Telangiectasia and Rad3-Related Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors","volume":"11","author":"Yap","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ygyno.2021.08.024_bb0155","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.pharmthera.2014.12.001","article-title":"ATM and ATR as therapeutic targets in cancer","volume":"149","author":"Weber","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ygyno.2021.08.024_bb0160","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","article-title":"ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response","volume":"66","author":"Blackford","year":"2017","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ygyno.2021.08.024_bb0165","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1158\/0008-5472.CAN-14-2593","article-title":"A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance","volume":"75","author":"Ceccaldi","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2021.08.024_bb0170","doi-asserted-by":"crossref","first-page":"942","DOI":"10.18632\/oncoscience.283","article-title":"Nucleotide excision repair (NER) alterations as evolving biomarkers and therapeutic targets in epithelial cancers","volume":"2","author":"Mouw","year":"2015","journal-title":"Oncoscience"},{"key":"10.1016\/j.ygyno.2021.08.024_bb0175","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/nrc3399","article-title":"DNA repair dysregulation from cancer driver to therapeutic target","volume":"12","author":"Curtin","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ygyno.2021.08.024_bb0180","doi-asserted-by":"crossref","first-page":"4780","DOI":"10.1158\/1078-0432.CCR-15-0479","article-title":"Molecular pathways: targeting ATR in Cancer therapy","volume":"21","author":"Karnitz","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2021.08.024_bb0185","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1158\/0008-5472.CAN-13-0110","article-title":"ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status","volume":"73","author":"Huntoon","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2021.08.024_bb0190","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1535-6108(03)00110-7","article-title":"Chk1 and Chk2 kinases in checkpoint control and cancer","volume":"3","author":"Bartek","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ygyno.2021.08.024_bb0195","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S1470-2045(20)30180-7","article-title":"Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial","volume":"21","author":"Konstantinopoulos","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ygyno.2021.08.024_bb0200","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-20-0868","article-title":"First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors","volume":"11","author":"Yap","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ygyno.2021.08.024_bb0205","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1200\/JCO.19.02404","article-title":"Phase I trial of first-in-class ATR inhibitor M6620 (VX-970) as Monotherapy or in combination with carboplatin in patients with advanced solid tumors","volume":"38","author":"Yap","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2021.08.024_bb0210","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1158\/1078-0432.CCR-16-2273","article-title":"Targeting the ATR\/CHK1 Axis with PARP inhibition results in tumor regression in BRCA-mutant ovarian Cancer models","volume":"23","author":"Kim","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2021.08.024_bb0215","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1038\/s41467-020-17127-2","article-title":"Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models","volume":"11","author":"Kim","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ygyno.2021.08.024_bb0220","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1101\/gad.290957.116","article-title":"ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells","volume":"31","author":"Yazinski","year":"2017","journal-title":"Genes Dev."},{"key":"10.1016\/j.ygyno.2021.08.024_bb0230","volume":"78","author":"Krebs","year":"2018"},{"key":"10.1016\/j.ygyno.2021.08.024_bb0235","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","article-title":"Homologous recombination deficiency (HRD) score predicts response to platinum-containing Neoadjuvant chemotherapy in patients with triple-negative breast Cancer","volume":"22","author":"Telli","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2021.08.024_bb0240","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2021.08.024_bb0245","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/jnci\/djh081","article-title":"Re: new guidelines to evaluate the response to treatment in solid tumors (ovarian cancer)","volume":"96","author":"Rustin","year":"2004","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2021.08.024_bb0250","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ygyno.2015.12.020","article-title":"Efficacy and safety of olaparib monotherapy in germline BRCA1\/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy","volume":"140","author":"Domchek","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.08.024_bb0255","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/annonc\/mdw133","article-title":"Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1\/2 mutation: a multistudy analysis of response rates and safety","volume":"27","author":"Matulonis","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2021.08.024_bb0260","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ygyno.2021.08.024_bb0265","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2016.69.9538","article-title":"Safety and activity of Mirvetuximab Soravtansine (IMGN853), a Folate receptor alpha-targeting antibody-drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary peritoneal Cancer: a phase I expansion study","volume":"35","author":"Moore","year":"2017","journal-title":"J. Clin. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821013226?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821013226?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:58:19Z","timestamp":1758772699000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825821013226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0090825821013226"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.08.024","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.08.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}